Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02214550 · ClinicalTrials.gov registry record · Phase 4
Chronic Pain Risk Associated With Menstrual Period Pain
A Phase 4 study, sponsored by Endeavor Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 353
- Enrollment target
NCT02214550 is a Phase 4 study that has completed, run by Endeavor Health. The registered enrollment target is 353 participants.
The verdict
NCT02214550, a Phase 4 study, has completed, sponsored by Endeavor Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 353 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if some women with dysmenorrhea (painful periods) are at higher future risk of developing chronic pelvic pain (CPP) and if oral contraceptives (OC) can be used to reverse this chronic pain risk. Investigators will examine whether dysmenorrhea produces CPP via repetitive cross organ sensitization (COS) episodes. The use of cyclical OCs to eliminate dysmenorrhea is expected to reduce COS and decrease the risk of developing CPP.
Interventions
- DRUG cyclic microgestin 1/20
- DRUG continuous microgestin 1/20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 353 participants |
| Start Date | 2014-07 |
| Est. Completion | 2021-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02214550
The ClinicalTrials.gov registry entry for NCT02214550 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 353 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Endeavor Health, which has 94 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which cyclic microgestin 1/20 is the first listed.
NCT02214550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02214550 about?
NCT02214550 is a clinical study titled "Chronic Pain Risk Associated With Menstrual Period Pain". The purpose of this study is to determine if some women with dysmenorrhea (painful periods) are at higher future risk of developing chronic pelvic pain (CPP) and if oral contraceptives (OC) can be used to reverse this chronic pain risk. Investigators will examine whether dysmenorrhea produces CPP v...
What is the current status of trial NCT02214550?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 353 participants. The study started on 2014-07. Estimated completion is 2021-01.
What interventions are being tested in trial NCT02214550?
The interventions under investigation include: cyclic microgestin 1/20 (DRUG), continuous microgestin 1/20 (DRUG).
Who is sponsoring clinical trial NCT02214550?
This trial is sponsored by Endeavor Health, which has 94 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.